Fundraising FoxShift Bioscience
Cambridge, GB · 5 known investors
Find your way into Shift Bioscience
Sign up to see every warm intro you have to Shift Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Shift Bioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis. The company works in the aging and longevity biotech field, having discovered novel aging targets linked to disease states.
Founders & leadership
Investors · 5
How we know: F-Prime Capital's portfolio page · shiftbioscience.com · Not right? Tell us
How we know: IKJ Capital's portfolio page · Not right? Tell us
How we know: Kindred Capital's portfolio page · funding news · shiftbioscience.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$16M disclosed across 1 round · 2024
- $16MSeed fundingOct 2024 · 3 sources
BGF (lead), F-Prime Capital, Kindred Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 6
Companies working in the same space as Shift Bioscience.
Companies House · registry record
View on Companies House ↗- Registered name
- SHIFT BIOSCIENCE LIMITED
- Company number
- 10793871
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 30 May 2017
- Registered office
- Salisbury House, Station Road, Cambridge, CB1 2LA
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- NEXTNEURAL LIMITED (2017–2017)
- Accounts
- last made up to 30 Jun 2025 · next due 31 Mar 2027
- Confirmation statement
- last made up to 13 Apr 2026 · next due 27 Apr 2027
Current officers · 8
- Andrew Fraley — director, appointed 13 Mar 2026
- Daniel Jeremy Ives — director, appointed 30 May 2017
- Jonathan Simon Milner — director, appointed 11 Jun 2024
- Alexander Thomas Pasteur — director, appointed 4 Feb 2022
- David Gifford Leathes Prior — director, appointed 1 Aug 2025
- Timothy Shan Rea — director, appointed 11 Jun 2024
- Laurence Edward Reid — director, appointed 1 Aug 2025
- Brendan Michael Swain — director, appointed 17 Jan 2022
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Shift Bioscience do?
- Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis. The company works in the aging and longevity biotech field, having discovered novel aging targets linked to disease states.
- Who founded Shift Bioscience?
- Shift Bioscience was founded by Daniel Ives, Brendan Swain.
- Who are Shift Bioscience's investors?
- Shift Bioscience's investors include F-Prime Capital, IKJ Capital, Kindred Capital, Cambridge Innovation Capital.
- How much funding has Shift Bioscience raised?
- Shift Bioscience has disclosed $16M raised across 1 round.
- Where is Shift Bioscience headquartered?
- Shift Bioscience is headquartered in Cambridge, GB.